JIXING is a leading biotechnology company headquartered in Shanghai committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.
Backed by RTW Investments, JIXING was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, industry leading talent, and patient-centric focus, JIXING is dedicated to deliver a meaningful and lasting impact on patients in Greater China.
Sandy Mou serves as Board Executive Director and Chief Executive Officer at JIXING. She is responsible for leading the full scope of business operations of the company.
Sandy Mou has nearly 30 years of experience in the pharmaceutical and medical device industry in China and has held management positions at several multinational pharmaceutical companies including GSK, AstraZeneca, Xi’an Janssen, Johnson & Johnson Medical and MSD. She has led teams to successfully launch several leading brands covering a wide range of therapeutic areas including cardiovascular and metabolic diseases, orthopedics, immunology and oncology. In May 2017, Sandy joined MSD China to establish the oncology business unit and oversaw several product launches including Keytruda. Under her leadership, the MSD China’s oncology business was ranked among the top three oncology businesses of multinational pharmaceutical companies in China after just three years. In March 2020, Sandy joined Shanghai Allist Pharmaceutical Technology Co. (Allist) as the Chief Executive Officer. During her tenure, Allist was successfully listed on the Science and Technology Board of the Shanghai Stock Exchange, achieved the first new drug approval, commercial launch and listing in the National Reimbursement Drug List. Under Sandy’s leadership, Allist has completed the transformation from a biotech company to an innovative biopharmaceutical company with integrated R&D, manufacturing and commercialization capabilities and has achieved profitability.
Sandy graduated from Shanghai Medical College of Fudan University with a bachelor's degree in Medicine and worked as a clinician for 7 years after graduation. Sandy also holds an EMBA degree from China Europe International Business School.
Kun Wu serves as Chief Commercial Officer at JIXING. Kun is responsible for developing JIXING’s commercial strategy and building a world-class team to drive the commercialization of its growing product portfolio.
Kun has more than 26 years of pharmaceutical experience with most of his career at Pfizer. He joined Pfizer China in 1995 as a medical representative and grew in roles of increasing responsibilities and organizational leadership. Prior to JIXING, he served as the China Chief Operating Officer at Pfizer Biopharma Group, leading a team with 5,000 people including Sales, Marketing, Key Accounts, Commercial and Business Operations. Prior to this role, Kun served as the China Country Lead at Pfizer Biopharma Group and as the China Country Lead of Pfizer Innovative Healthcare where he led the commercial team to achieve excellent performance and successfully launched multiple blockbuster products in the market.
Kun graduated from Anhui Medical University with a bachelor's degree in clinical medicine science. Kun also served as an orthopedic surgeon for 6 years.
Yuan Li, MD
Yuan Li, MD
Yuan Li, MD, serves as Chief Medical Officer of Cardiovascular at JIXING. Yuan is responsible to provide leadership and direction for the clinical development of JIXING’s pipeline. As CMO of Cardiovascular, Yuan provides essential medical expertise and drives clinical development strategy and execution, ensuring the approval of JIXING’s new drugs in China.
Before joining JIXING, Yuan worked as Senior Director, Head of Project Management for the China Development Center at Merck & Co., Inc. (“Merck” or “MSD”). Over a nine-year tenure, Yuan built new functional capabilities in pharmaceutical project management, oversaw the clinical development programs across multiple therapeutic areas, and steered the MSD pipeline through the quickly evolving regulatory environment. Before joining MSD, Yuan worked in R&D at AstraZeneca China for seven years, covering roles in medical affairs and clinical development.
Yuan received her medical doctor degree from Peking University Health Science Center, majoring in the cardiovascular area. Following her studies, she worked in the Peking University People’s Hospital as a physician for several years before moving into industry roles.
Larry Zhiping Li, MD, PhD
Larry Zhiping Li, MD, PhD
Larry serves as Chief Medical Officer of Ophthalmology at JIXING. Larry is responsible to advance JIXING’s pipeline of ophthalmology assets incl. clinical development strategy, its execution and ensuring the approval of JIXING’s new products in China. Given Larry’s strong academic background and extensive collaboration, he will be a key driver of JIXING’s step print both in scientific and clinical areas.
Before joining JIXING, Larry was the Medical Director for Alcon APAC/China/Japan regions, based in Singapore. Over the last two decades, he has been involved in various international projects of translational medicine and new product development for diabetic retinopathy, proliferative vitreoretinopathy, glaucoma, cataract, refractive surgeries and ocular surface diseases, as well as next-generation drug delivery system for various eye diseases treatment and functional OCT for disease diagnosis. Along this journey, he has established and nurtured ophthalmic drugs/devices/solutions development team comprised a few dozens of professionals who benefited greatly from his focus on sustainable growth of talents.
Larry has a Medical Degree from Shanghai Medical University, China. He also obtained a Master’s Degree in Ophthalmology followed by a Doctoral Degree (equivalent to PhD) from Shanghai Medical School, Fudan University, China. During his academic time abroad, Larry obtained a Master’s Degree (M.Sc.) in Medical Optics, Applied Physics from the Kirchhoff Institute of Physics at University of Heidelberg, Germany.
Ying Wang serves as Chief Business Officer at JIXING. Ying is responsible to manage the Strategic and Corporate Development team including development and execution of the alliance management and partnering strategy.
Before joining JIXING, Ying worked as Co-founder and CEO of the Zhongkong Virtual Hospital Group in Beijing. In this role, she built an innovative digital commercial platform and successfully sold the company after three years. Previously, she served as Chief of Staff to the Regional President of Pfizer China, where she worked side by side with the Leadership Team, operating as a senior-level operations liaison and thought partner. Lastly, Ying gained working experience in the United States at Pfizer’s headquarters, TargetRx, AIG and Mercer.
Ying received her EMBA from The Wharton School of the University of Pennsylvania and dual master’s degrees in applied mathematics and statistics from the University of Delaware.
Rainy (Yucong) Zhou serves as Senior Vice President, Regulatory Affairs at JIXING. Rainy is responsible to lead all of JIXING's Regulatory Affair activities and communications with regulatory agencies, as well as the design of the clinical development and registration strategy for each of JIXING's assets in China.
Rainy has more than 20 years of industry experience in Regulatory Affairs at Multinational Pharmaceutical Companies across several therapeutic areas. Before joining JIXING, Rainy worked at Novartis for seven years as Director Regulatory Affairs, overseeing the therapeutic areas of Immunology, Hepatology, Dermatology and Transplant, and contributing to the development of Novartis’ regulatory strategy for a pipeline of new products. She led the team through the successful submission and approvals of several CTAs and NDAs, meanwhile maintaining marketed products. Prior to joining Novartis, Rainy worked at Sanofi, Eli Lily and Bayer, covering numerous therapeutic areas including Cardiovascular, CNS, Women’s Health and Diabetes. Rainy has also been strongly involved in shaping the policy ecosystem in the past years in China.
Rainy holds a master’s degree in Clinical Medicine from Nankai University.
Yi Yan serves as Senior Vice President, Clinical Operations at JIXING. In this role, Yi oversees the clinical operations, including building the team and supporting the design of strategies crucial for the company’s growth and success.
Before joining JIXING, Yi worked as Executive Director, Head of Clinical Operations in dMed for three years. Prior to dMed, she worked at Pfizer for 20 years including legacy Pharmacia, in each role leading clinical operations and compliance oversight of global clinical trials execution.
Yi received her bachelor’s degree from the Second Medical University of Shanghai. As a medical doctor, she gathered first-hand experience as a practicing physician in The Ninth People’s Hospital of Shanghai for 13 years.
Christine Dai serves as Chief Human Resources Officer of JIXING. In this role, Christine will lead the HR team and collaborate with JIXING's Leadership Team to define and develop the strategic direction and key approaches for organization & talents’ development. She will also refine, land and evolve the differentiated corporate culture of JIXING, for the sustainable growth of organization, business and talents.
Before joining JIXING, Christine worked as HR Head of Speiyou in TAL Education which is a fast-growing top K12 Education Group with more than 30K employees in China from May 2020 till October 2021. Before that she held the role of HR VP/ HR General Manager in Fosun Pharma responsible for the overall HR management of Fosun Pharma HQ and membership enterprises with more than 20K employees worldwide. Prior to Fosun, she worked at Novartis for more than 16 years, and served in diverse roles with increasing responsibilities, including HR Manager of Shared Service Center, HRBP Head of Specialty BUs, HR Head of GCPO Beijing (Greater China Pharma Organization-North China), HR Head of OTC Greater China & South Korea, HR Head of NBS (Novartis Business Services) Greater China, and Head of TAS (Talent Acquisition & Staffing) Greater China. Before Novartis, Christine started her career at China International Intellectech Co. Ltd. (CIIC), a SOE HR outsourcing & consulting services’ provider, as business representative.
Christine received her bachelor’s degree in English literature from China University of Political Science and Law and a BiMBA diploma from Novartis-Beijing University BiMBA program, as well as a diploma from Novartis-IMD Emerging Leadership Program.
Lisa Tian serves as VP, Chief Finance Officer of JIXING. In this role, Lisa will oversee the entire Finance function including Treasury, Tax, Accounting, Procurement, FP&A, and Internal Controls. In addition, Lisa will oversee IT and investor relations. She will partner with the senior leadership team and Board of Directors on decision making and strategy development of the business and act as a strong advisor to the board on business direction from financial perspective, including capital raising.
Before joining JIXING, Lisa worked as Finance Head of Innocare which is a fast-growing Bio-pharma including R&D, manufacturing and commercialization from Sep 2020 till Jun 2022. During her time at Innocare, Lisa supported their post HKex Finance operations and involved in their A-listing process in STAR board. Before that she held the role of deputy CFO in Fosun Pharma-Medical device, mainly responsible for the overseas medical device finance and business operations in mainland China & HK. Prior to Fosun, she worked at Novartis & Alcon for more than 5 years, and served in diverse roles with increasing responsibilities, including Greater China FRA Head and Country Lead of SAP project. She also worked in GE Healthcare acted as GPRS Asia Finance Head, then relocated to GE Healthcare US HQ as global FP&A. Prior of GE Healthcare, Lisa served in pharmaceutical companies like Bayer Healthcare, Sanofi-Aventis etc.
Lisa received her bachelor’s degree of Economics in The Capital of Business & Economics University, and she is an Associate Member of AAIA.
Horch Guo serves as Vice President, Head of TechOps at JIXING. In this position, Horch leads Supply Chain, Production, Quality, Engineering and CMC functions. He is responsible for developing and implementing manufacturing strategies, procedures, organization & budget plans to strengthen the in-license products’ portfolio with efficient technology transfer, robust local manufacturing, quick product launch and reliable supply chain.
Horch brings rich technical operations and team management experience in pharmaceutical industry. Prior to joining JIXING, Horch was Site Head of Everest Medicines for the overall site management (Jiashan Site), and the Deputy General Manager of Luoxin Aurovitas Pharma (Chengdu) where he acted as the General Manager being responsible for the entire site operation and management, product introduction strategy, tech transfer and financial management etc. Before joining Luoxin, Horch ever worked in Edding Pharma, Roche, Bayer and Sanofi respectively with experiences of license-in, process development, technology transfer, manufacturing operations, engineering, CAPEX & investment management, Joint Venture/Company setup and operation etc. with increasing responsibilities.
Horch obtained his Bachelor’s and Master’s degree of pharmaceutics from China Pharmaceutical University and Shanghai Institute of Pharmaceutical Industry respectively. Horch also obtained his Master’s degree of Financial Management from Shanghai University of Finance and Economics.
John Li serves as Vice President, General Counsel & Chief Compliance Officer at JIXING. John is responsible for leading the Legal & Compliance function to provide professional legal advice and solutions to facilitate execution of JIXING’s business strategy. He works closely with leadership team to build a robust compliance program to further enhance JIXING’s compliance culture.
Before joining JIXING, John worked as General Counsel and VP of Legal & Compliance Department at Burning Rock which is a Nasdaq-listed leading diagnostic company with business presence in both China and US. Before that he was Legal Head of Nutrition BG and Legal Head of Diagnostic BG of Abbott China, a Fortune 500 healthcare company. Prior to Abbott, John worked for several leading US law firms including Latham, MOFO and Orrick, where he advised international and domestic clients on general corporate, private equity and capital market matters.
John received his bachelor’s degree and master’s degree in law from Fudan University, as well as his master’s degree in law from Columbia University in NYC. He passed China national judicial exam and was admitted to New York Bar.
Vicky Wang serves as Vice President, Head of Medical Affairs at JIXING. In this position, Vicky will be responsible for building a strong Medical Affairs function and developing the medical strategy that support JIXING’s commercialization success in China, particularly in launch preparation and post-launch medical support.
Vicky brings more than 13-years of experience in medical leadership roles with a proven record in both multinational and domestic pharmaceutical companies. Prior to JIXING, Vicky worked as Head of Medical at Salubris Pharmaceuticals, leading multiple functions including Medical Advisor, Medical Science Liaison, Medical Information, Clinical Operations and Pharmacovigilance. Prior to Salubris, Vicky had worked in leading pharmaceutical companies including Bayer, Pfizer and Novartis with increasing responsibilities. Vicky started her career at Peking University Third Hospital as a trained cardiologist and then a board-certified oncologist.
Vicky holds a medical master degree in cardiovascular medicine from Peking University and a Ph.D. in Biomedical Research from University College London. She also graduated diploma programs of Applied Psychology from Peking University and an online MBA Management Development Program at the Wharton School from University of Pennsylvania.